Cite
HARVARD Citation
Edlund, H. et al. (2022). Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. British journal of clinical pharmacology. 88 (5), pp. 2284-2296. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Edlund, H. et al. (2022). Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. British journal of clinical pharmacology. 88 (5), pp. 2284-2296. [Online].